BGOG-cx-8
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax® ®-TF -ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer
Sponsor: Genmab
Participating sites:
- UZ Leuven, Leuven
- CHU de Liège, site Sart Tilman, Liège
- UZ Antwerpen, Antwerpen
- CHU UCL St-Luc, Bruxelles
- Grand Hôpital de Charleroi, Charleroi
- CHU UCL St-Luc, Bruxelles
- AZ Sint-Jan Brugge, Brugge
- UZ Gent, Gent
- Hôpital de Libramont, Libramont
Learn More ->
BGOG-cx-11
A randomized, Phase 3, double-blind study of radiochemotherapy with or without Pembrolizumab for the treatment of high-risk, locally advanced cervical cancer
Sponsor: Merck Sharp & Dohme Corp.
Participating sites:
- AZ Sint-Lucas, Gent
- UZ Leuven, Leuven
- GZA campus Sint-Augustinus, Antwerpen
- OLV Aalst, Aalst
- CHU Ambroise Paré, Mons
- UZA, Antwerpen
Learn More ->
